Rat Monocyte Chemoattractant Protein (MCP-1) is a member of the C-C chemokine superfamily and a homolog of human MCP-1. MCP-1 is expressed by a variety of cell types including monocyte/macrophages, endothelial cells and mesangial cells.3 MCP-1 has chemoattractant activity for monocytes, lymphocytes and basophils but is not active for neutrophils. Recombinant rat MCP-1 is a highly glycosylated protein ranging in size from 27 - 30 kD as measured by SDS-PAGE analysis. Furthermore, there is evidence from experimental animal models that MCP-1 can suppress tumor formation by attracting monocytes to the tumor site.Recombinant rat MCP-1 (MN 555110) is supplied as a frozen liquid comprised of 0.22 μm sterile-filtered aqueous buffered solution containing glycerol and 1.0 mg/ml bovine serum albumin, with no preservatives. Recombinant rat MCP-1 is ≥ 95% pure as determined by SDS-PAGE, and an absorbance assay based on the Beers-Lambert law. The endotoxin level is ≤ 0.1 ng per µg of rat MCP-1, as measured in a chromogenic LAL assay.
Purified Mouse Anti-Rat MCP-1 C4RUO 0.5mgCat No: 555072
Biotin Mouse Anti-Rat MCP-1 B4RUO 0.5mgCat No: 555074
Rat MCP-1 ELISA Set RUO 20Cat No: 555130
TMB Substrate Reagent Set RUO Cat No: 555214
PE Hamster Anti-Mouse/Rat MCP-1 2H5RUO 0.1mgCat No: 554443
Resources & Tools | ||||||
---|---|---|---|---|---|---|
SpectrumViewer | Download TDS | Regulatory Document Website |
Store product at -80°C prior to use or for long term storage of stock solutions.Rapidly thaw and quick-spin product prior to use.Avoid multiple freeze-thaws of product.This preparation contains no preservatives, thus it should be handled under aseptic conditions.
Upon initial thawing, recombinant rat MCP-1 (MN 555110) should be aliquoted into polypropylene microtubes and frozen at -80°C for future use. Alternatively, the product can be diluted in sterile neutral buffer containing not less than 0.5 - 10 mg/mL carrier protein, such as human or bovine albumin, aliquoted and stored at -80°C.For in vitro biological assay use, carrier-protein concentrations of 0.5 - 1 mg/mL are recommended. For use as an ELISA standard, carrier-protein concentrations of 5 - 10 mg/mL are recommended. Failure to add carrier protein or store at indicated temperatures may result in a loss of activity.Carrier proteins should be pre-screened for possible affects in each investigator"s experimental system. Carrier proteins may have an undesired influence on experimental results due to toxicity, high endotoxin levels or possible blocking activity.
ELISA Standard:Recombinant rat MCP-1 (MN 555110) can be useful as a quantitative standard for measuring rat MCP-1 protein levels using sandwich ELISA with the purified C4 antibody (Cat. No. 555072) as a capture antibody and the biotinylated B4 antibody (Cat. No. 555074) as the detection antibody. To obtain linear standard curves, investigators may want to consider using doubling dilutions of recombinant rat MCP-1 from 2000-5 pg/mL to be included for each ELISA plate.For measuring rat MCP-1 in serum or plasma, investigators are highly encouraged to use the BD OptEIA™ Rat MCP-1 Set (Cat. No. 555130).
Bioassay: Investigators are advised that the Bioassay application is not routinely tested for this material and are highly encouraged to both titrate this material and include appropriate controls in relevant experiments.An activity range encompassing an ED50 = 60 - 600 ng/mL has previously been reported using THP-1 as indicator cells utilizing a calcium flux assay.
Ligand Blocking Control for Immunofluorescent Staining of Cytokines:Recombinant rat MCP-1 can be used as a blocking control to demonstrate the specificity of MCP-1 staining by the PE-conjugated format (Cat. No.554443) of the 2H5 Anti-Rat MCP-1 antibody. Investigators are advised that this blocking application is not routinely tested for this material.The use of staining controls for the immunofluorescent staining and flow cytometric analysis of cytokine producing cells has been previously described (Prussin et al.).
BD是世界上最大的生产和销售医疗设备、医疗系统和试剂的医疗技术公司之一。致力于提高全世界人类的健康水平。BD专注于改进药物治疗,提高传染性疾病诊断的质量和速度,推进新型药物和疫苗的研究与发现。公司于1897年在纽约成立,总部位于美国新泽西州的富兰克林湖,业务可分为BD医疗、BD诊断、BD生物科学三大类,生产销售包括医用耗材、实验室仪器、抗体、试剂、诊断等产品。